Association Between Increased Platelet P-Selectin Expression and Obesity in Patients With Type 2 Diabetes A BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
19/10/2012
19/10/2012
2009
|
Resumo |
OBJECTIVE- To determine whether obesity increases platelet reactivity and thrombin activity in patients with type 2 diabetes plus stable coronary artery disease. RESEARCH DESIGN AND METHODS- We assessed platelet reactivity and markers of thrombin generation and activity in 193 patients from nine clinical sites of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Blood taken at the time of enrollment was used for assay of the concentration of prothrombin fragment 1.2 (PT1.2, released when prothrombin is activated) and fibrinopeptide A (FPA, released when fibrinogen is cleaved). Platelet activation was identified with the use of flow cytometry in response to 0, 0.2, and 1 mu mol/l adenosine diphosphate (ADP). RESULTS- Concentrations of FPA, PT1.2, and platelet activation in the absence of agonist were low. Greater BMI was associated with higher platelet reactivity in response to 1 mu m ADP as assessed by surface expression of P-selectin (r = 0.29, P < 0.0001) but not reflected by the binding of fibrinogen to activated glycoprotein IIb-IIIa. BMI was not associated with concentrations of FPA or PT1.2. Platelet reactivity correlated negatively with A1C (P < 0.04), was not related to the concentration Of triglycerides in blood, and did not correlate with the concentration of C-reactive peptide. CONCLUSIONS- Among patients enrolled in this substudy of BARI 2D, a greater BMI was associated with higher platelet reactivity at the time of enrollment. Our results suggest that obesity and insulin resistance that accompanies obesity may influence platelet reactivity in patients with type 2 diabetes. National Heart, Lung, and Blood Institute (NHLBI/NIH)[R01 HL69146] National Heart, Lung, and Blood Institute (NHLBI/NIH)[R01 HL71306] NHLBI[U01 HL061746] NHLBI[U01 HL06171748] NHLBI[U01 HL06384] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH)[HL061744] |
Identificador |
DIABETES CARE, v.32, n.5, p.944-949, 2009 0149-5992 http://producao.usp.br/handle/BDPI/21249 10.2337/dc08-1308 |
Idioma(s) |
eng |
Publicador |
AMER DIABETES ASSOC |
Relação |
Diabetes Care |
Direitos |
restrictedAccess Copyright AMER DIABETES ASSOC |
Palavras-Chave | #C-REACTIVE PROTEIN #NONDIABETIC PATIENTS #FIBRINOPEPTIDE-A #WEIGHT-REDUCTION #BLOOD #ACTIVATION #ASPIRIN #TRIAL #ATHEROSCLEROSIS #DETERMINANT #Endocrinology & Metabolism |
Tipo |
article original article publishedVersion |